US · BGM · DRUG MANUFACTURERS - SPECIALTY & GENERIC
BGM Group Ltd. (BGM) intrinsic value and stock valuation
$7.22as of 2026-11-21 · Mkt cap 59.61M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
BGM Group Ltd. DCF and intrinsic value
InvestorsCraft values BGM with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from BGM’s statements →
BGM Group Ltd. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2017–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
- Twist Bioscience Corporation (TWST) $103.32
- Edgewise Therapeutics, Inc. (EWTX) $39.91
- Structure Therapeutics Inc. (GPCR) $16.13
- Clover Health Investments, Corp. (CLOV) $3.73
- Mesoblast Limited (MESO) $10.89
- ANI Pharmaceuticals, Inc. (ANIP) $68.55
- Phibro Animal Health Corporation (PAHC) $33.29
- QuidelOrtho Corporation (QDEL) $8.32
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $37.9M | $25.1M | $46.5M | $64.9M | $57.1M |
| Operating income | -$-12.58M | -$-560K | -$-2.61M | $2.1M | $2.39M |
| Net income | -$-19.94M | -$-1.44M | -$-7.78M | $1.08M | $3.15M |
| EPSd | -$-176.06K | -$-199.17K | -$-1.08M | $149.4K | $461.9K |
| Operating cash flow | -$-2.37M | $540K | $310K | $12.7M | $350K |
| Capital expenditure | -$-2.07M | -$-3.93M | -$-3.71M | -$-3.26M | -$-3.49M |
| Free cash flow | -$-4.44M | -$-3.39M | -$-3.4M | $9.4M | -$-3.15M |
| Total assets | $433.8M | $53M | $51.3M | $64.5M | $75.4M |
| Total debt | $1.94M | $0.00 | $580K | $1.77M | $8.03M |
| Net debt | -$-7.88M | -$-9.82M | -$-6.9M | -$-12.55M | -$-2.44M |
| Total equity | $391.9M | $44.1M | $44.4M | $55M | $56.7M |
| Cash and short-term investments | $10.8M | $18.1M | $22.4M | $14.3M | $10.5M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $37.9M | $25.1M | $46.5M | $64.9M | $57.1M |
| Cost of revenue | $33.1M | $21M | $44.7M | $58.6M | $51.5M |
| Gross profit | $4.85M | $4.11M | $1.75M | $6.23M | $5.64M |
| Research and development expenses | $670K | $1.36M | $570K | $1.22M | $0.00 |
| Selling, general and administrative expenses | $16.8M | $3.32M | $3.79M | $2.9M | $3.25M |
| Other expenses | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating expenses | $17.4M | $4.68M | $4.36M | $4.13M | $3.25M |
| Cost and expenses | $50.5M | $25.7M | $49.1M | $62.8M | $54.7M |
| Interest income | $80K | $0.00 | $100K | $20K | $0.00 |
| Interest expense | $0.00 | $640K | $0.00 | $0.00 | $60K |
| Depreciation and amortization | $1.46M | $1.24M | $1.14M | $1.22M | $1.2M |
| Ebitda | -$-11.12M | $880K | -$-1.27M | $3.74M | $4.15M |
| Operating income | -$-12.58M | -$-560K | -$-2.61M | $2.1M | $2.39M |
| Total other income/expenses, net | -$-7.36M | -$-1.57M | -$-5.29M | -$-540K | $980K |
| Income before tax | -$-19.94M | -$-2.14M | -$-7.9M | $1.56M | $3.36M |
| Income tax expense | $280K | -$-620K | $220K | $190K | $260K |
| Net income | -$-19.94M | -$-1.44M | -$-7.78M | $1.08M | $3.15M |
| Weighted average shares outstanding | $113.3M | $7.23M | $7.23M | $7.23M | $6.82M |
| Weighted average diluted shares outstanding | $113.3M | $7.23M | $7.23M | $7.23M | $6.82M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $10.8M | $18.1M | $22.4M | $14.3M | $10.5M |
| Net receivables | $17.1M | $5.77M | $6.35M | $4.87M | $13.5M |
| Inventory | $23.7M | $5.05M | $4.99M | $8.88M | $12.5M |
| Total current assets | $51.6M | $29.8M | $34.5M | $30M | $40.4M |
| Property, plant and equipment, net | $15.1M | $14.9M | $12.7M | $12.3M | $11.5M |
| Goodwill and intangible assets | $355.3M | $4.54M | $3.42M | $1.73M | $1.93M |
| Long-term investments | $11.5M | $3.36M | $610K | $20.1M | $21M |
| Total non-current assets | $382.3M | $23.2M | $16.8M | $34.5M | $35M |
| Total assets | $433.8M | $53M | $51.3M | $64.5M | $75.4M |
| Accounts payable | $6.56M | $4.13M | $3.59M | $5.29M | $6.64M |
| Short-term debt | $1.86M | $0.00 | $550K | $1.7M | $7.92M |
| Deferred revenue | $3.14M | $570K | $1.11M | $680K | $2.84M |
| Total current liabilities | $41.6M | $8.78M | $6.66M | $9.18M | $18.2M |
| Long-term debt | $80K | $0.00 | $20K | $70K | $110K |
| Deferred revenue, non-current | $0.00 | $130K | $220K | $310K | $400K |
| Total non-current liabilities | $80K | $130K | $250K | $380K | $510K |
| Capital lease obligations | $80K | $0.00 | $100K | $100K | $160K |
| Total liabilities | $41.7M | $8.91M | $6.91M | $9.56M | $18.7M |
| Common stock | $1.67M | $60K | $60K | $60K | $60K |
| Retained earnings | -$-15.78M | $4.35M | $5.9M | $15.5M | $14.7M |
| Accumulated other comprehensive income (loss) | $5.97M | $1.92M | $430K | $1.07M | $3.71M |
| Total equity | $391.9M | $44.1M | $44.4M | $55M | $56.7M |
| Total investments | $12.5M | $11.7M | $15.6M | $20.1M | $21M |
| Total debt | $1.94M | $0.00 | $580K | $1.77M | $8.03M |
| Net debt | -$-7.88M | -$-9.82M | -$-6.9M | -$-12.55M | -$-2.44M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-19.94M | -$-1.52M | -$-8.12M | $1.37M | $3.11M |
| Depreciation and amortization | $1.46M | $1.24M | $1.14M | $1.22M | $1.2M |
| Stock-based compensation | $0.00 | $0.00 | $0.00 | $20K | $0.00 |
| Change in working capital | -$-3.19M | $790K | $1.11M | $8.75M | -$-3.67M |
| Accounts receivable | -$-2.97M | $1.33M | -$-2.89M | $9.77M | -$-160K |
| Inventory | $850K | $960K | $3.4M | $2.23M | $50K |
| Accounts payable | -$-1.83M | $380K | -$-1.62M | -$-810K | $2.02M |
| Net cash provided by operating activities | -$-2.37M | $540K | $310K | $12.7M | $350K |
| Investments in property, plant and equipment | -$-2.19M | -$-2.85M | -$-1.85M | -$-3.23M | -$-3.49M |
| Acquisitions, net | $2.39M | $0.00 | -$-30K | $0.00 | -$-710K |
| Net cash used for investing activities | -$-160K | $980K | -$-4.74M | -$-3.26M | -$-24.2M |
| Common stock issued | $0.00 | $0.00 | $0.00 | $0.00 | $23.9M |
| Common stock repurchased | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | -$-1.79M | $0.00 | $0.00 |
| Net cash used for financing activities | $2.62M | -$-490K | -$-2.92M | -$-5.94M | $24M |
| Net change in cash | $0.00 | $2.34M | -$-7.5M | $2.37M | $740K |
| Cash at end of period | $9.82M | $9.82M | $7.48M | $15M | $12.6M |
| Operating cash flow | -$-2.37M | $540K | $310K | $12.7M | $350K |
| Capital expenditure | -$-2.07M | -$-3.93M | -$-3.71M | -$-3.26M | -$-3.49M |
| Free cash flow | -$-4.44M | -$-3.39M | -$-3.4M | $9.4M | -$-3.15M |
Line items
Line items
Line items
About BGM Group Ltd.
Operating from Chengdu, People's Republic of China, BGM Group Ltd. engages in the manufacturing and supply of active pharmaceutical ingredients (APIs), traditional Chinese medicine (TCM) derivatives, and various other related products across China. The company's pharmaceutical portfolio includes an array of licorice-based items: Gan Di Xin, an oral medication for cough and expectorant relief; Qilian Shan Licorice Extract, serving as a raw material for pharmaceutical firms to produce conventional licorice tablets; and Qilian Shan licorice liquid extract, a key ingredient utilized by medical preparers for crafting compound licorice oral solutions. BGM also provides Qilian Shan oxytetracycline tablets, formulated to prevent and treat a range of ailments in poultry (chickens, turkeys), livestock (cattle, swine), and humans, in addition to Qilian Shan oxytetracycline APIs for use by pharmaceutical manufacturers. Beyond APIs, the company produces TCM derivatives such as Ahan antibacterial paste, which is designed for managing stubborn chronic skin conditions. Its diverse offerings also encompass heparin products, including heparin sodium preparations essential for pharmaceutical companies developing treatments for cardiovascular and cerebrovascular diseases, as well as hemodialysis applications. Furthermore, BGM supplies natural food products like Zhu Xiaochang sausage casings for culinary use. In the agricultural sector, it offers Xiongguan organic fertilizers, which enhance crop yields, improve soil chemical characteristics, and alleviate compaction, alongside Xiongguan organic-inorganic compound fertilizers engineered to promote superior plant development. Established in 2019, the company operated as Qilian International Holding Group Limited until adopting its current name, BGM Group Ltd, in October 2024.
- CEO
- Chen Xin
- Employees
- 298
- Beta
- 1.79
Explore
Frequently asked questions
What is the intrinsic value of BGM Group Ltd. (BGM)?
BGM Group Ltd. (BGM) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is BGM undervalued?
BGM trades at a price of $7.22 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.